Hospitals Urge Drug Maker to Reverse Policy
On Supplying Avastin, Rituxan, & Herceptin
Cancer centers and other hospitals, reeling from the loss of discounts and rebates on three widely used cancer drugs, are seeking to persuade drug maker Genentech to reverse its decision to channel these medications through six specialty distributors.
Until Oct. 1, Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan (rituximab) could be ordered from wholesalers, which provided discounts and rebates on large purchases. Genentech is a unit of Roche.
The company’s switch to specialty distributors, in effect, eliminated these benefits.